{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:00:52Z","timestamp":1793779252058,"version":"4.6.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T00:00:00Z","timestamp":1522972800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1038\/s41574-018-0001-9","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T10:18:48Z","timestamp":1523528328000},"page":"326-328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Does lower limb amputation concern all SGLT2 inhibitors?"],"prefix":"10.1038","volume":"14","author":[{"given":"Andr\u00e9 J.","family":"Scheen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,6]]},"reference":[{"key":"1_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.02.001","author":"D Li","year":"2018","unstructured":"Li, D. et al. Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Metab. \n                    https:\/\/doi.org\/10.1016\/j.diabet.2018.02.001\n                    \n                   (2018).","journal-title":"Diabetes Metab."},{"key":"1_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644\u2013657 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13255","author":"C Khouri","year":"2018","unstructured":"Khouri, C., Cracowski, J. L. & Roustit, M. SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect? Diabetes Obes. Metab. \n                    https:\/\/doi.org\/10.1111\/dom.13255\n                    \n                   (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"1_CR4","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2337\/dc17-1551","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi, S. E. et al. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41, e4\u2013e5 (2018).","journal-title":"Diabetes Care"},{"key":"1_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00592-016-0928-z","volume":"54","author":"M Monami","year":"2017","unstructured":"Monami, M. et al. Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials. Acta Diabetol. 54, 411\u2013413 (2017).","journal-title":"Acta Diabetol"},{"key":"1_CR6","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","volume":"34","author":"S Kohler","year":"2017","unstructured":"Kohler, S. et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv. Ther. 34, 1707\u20131726 (2017).","journal-title":"Adv. Ther."},{"key":"1_CR7","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/dom.13124","volume":"20","author":"S Jabbour","year":"2018","unstructured":"Jabbour, S. et al. Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb\/III clinical trials. Diabetes Obes. Metab. 20, 620\u2013628 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"1_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.031227","author":"JA Udell","year":"2017","unstructured":"Udell, J. A. et al. Cardiovascular outcomes and risks after initiation of a sodium glucose co-transporter 2 inhibitor: results from the EASEL population-based cohort study. Circulation \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.031227\n                    \n                   (2017).","journal-title":"Circulation"},{"key":"1_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/dom.13115","volume":"20","author":"Z Yuan","year":"2018","unstructured":"Yuan, Z. et al. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort study. Diabetes Obes. Metab. 20, 582\u2013589 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"1_CR10","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","volume":"5","author":"G Fadini","year":"2017","unstructured":"Fadini, G. & Avogaro, A. SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol. 5, 680\u2013681 (2017).","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41574-018-0001-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41574-018-0001-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41574-018-0001-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:45:22Z","timestamp":1684619122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-018-0001-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1"],"URL":"https:\/\/doi.org\/10.1038\/s41574-018-0001-9","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,6]]},"assertion":[{"value":"6 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}